Site search
2855 results for '' found
DREAMM7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with t
DREAMM7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with t
/
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD (ACTRN12622001458729)
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD (ACTRN12622001458729)
/
Validation of the Discovery NM 530c, dedicated cardiac camera, for the measurement of left ventricular ejection fractions with gated cardiac blood-pool imaging using the current Alfred protocol (
Validation of the Discovery NM 530c, dedicated cardiac camera, for the measurement of left ventricular ejection fractions with gated cardiac blood-pool imaging using the current Alfred protocol (
/
A multi-centre, open-label innovation study in pancreatic cancer utilising Nanoknife® System for Irreversible Electroporation (IRE) in unresectable stage 3 pancreatic adenocarcinoma (ACTRN126210
A multi-centre, open-label innovation study in pancreatic cancer utilising Nanoknife® System for Irreversible Electroporation (IRE) in unresectable stage 3 pancreatic adenocarcinoma (ACTRN126210
/
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardio
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardio
/
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) (N
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) (N
/
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer [DeL
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer [DeL
/
Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect: Guided Physiologic Stenting (short title: DEFiNE GPS) (NCT04451044)
Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect: Guided Physiologic Stenting (short title: DEFiNE GPS) (NCT04451044)
/
The effect of substantial weight loss with tirzepatide on heart failure with preserved ejection fraction in people with obesity (ACTRN12624000270516)
The effect of substantial weight loss with tirzepatide on heart failure with preserved ejection fraction in people with obesity (ACTRN12624000270516)
/
DExmedetomidine in Cardiac surgical Intraoperative Drug Evaluation (ACTRN12623001171606)
DExmedetomidine in Cardiac surgical Intraoperative Drug Evaluation (ACTRN12623001171606)
/